Senti Bio announces additional $11.5M in financing

Senti Bio (SNTI)sciences has secured an additional investment of approximately $10.0 million in gross proceeds from Celadon Partners adding to the previously announced PIPE financing round. This additional funding brings the total raised in the round to $47.6 million. The PIPE financing, announced on December 2, 2024, was led by Celadon Partners, with participation from New Enterprise Associates, Leaps by Bayer, Nantahala Capital, The Red Hook Fund LP, and other institutional and accredited investors. The Company intends to use the net proceeds from the offering, together with existing cash, cash equivalents and investments, to fund the continued development of its SENTI-202 program and manufacturing ramp-up, other research and development activities, and for general corporate purposes. Leerink Partners acted as the placement agent for the PIPE financing. In addition, on January 1, 2025, the Company also received an additional $1.5 million from its $8 million grant from the California Institute for Regenerative Medicines that was first announced in June 2024, which brings the total CIRM amount received by the Company to $6.4 million.